Marker Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Marker Therapeutics şirketinin kazançlarının yıllık 38.9% oranında düşmesi, yıllık gelirinin ise yıllık 70.7% oranında artması bekleniyor. EPS'nin yıllık 10.4% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-38.9%

Kazanç büyüme oranı

-10.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.6%
Gelir büyüme oranı	70.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29

Marker Therapeutics EPS misses by $0.02

Nov 09

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:MRKR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	2	-67	N/A	N/A	1
12/31/2025	4	-44	N/A	N/A	1
12/31/2024	5	-11	N/A	N/A	1
9/30/2024	5	-10	-9	-9	N/A
6/30/2024	4	-10	-11	-11	N/A
3/31/2024	3	-12	-14	-14	N/A
12/31/2023	3	-14	-16	-16	N/A
9/30/2023	3	-14	-20	-20	N/A
6/30/2023	4	-17	-27	-27	N/A
3/31/2023	4	-14	-18	-21	N/A
12/31/2022	4	-20	-27	-27	N/A
9/30/2022	4	-26	-26	-26	N/A
6/30/2022	3	-33	-27	-25	N/A
3/31/2022	2	-43	-36	-31	N/A
12/31/2021	1	-42	-30	-27	N/A
9/30/2021	N/A	-41	-35	-28	N/A
6/30/2021	N/A	-36	-34	-27	N/A
3/31/2021	0	-31	-35	-24	N/A
12/31/2020	0	-29	-29	-20	N/A
9/30/2020	1	-25	-24	-19	N/A
6/30/2020	1	-23	-23	-19	N/A
3/31/2020	0	-23	-19	-19	N/A
12/31/2019	0	-21	-19	-18	N/A
9/30/2019	N/A	-152	-20	-20	N/A
6/30/2019	N/A	-151	-18	-18	N/A
3/31/2019	0	-150	-16	-16	N/A
12/31/2018	0	-148	-15	-14	N/A
9/30/2018	0	-15	-11	-11	N/A
6/30/2018	0	-15	N/A	-9	N/A
3/31/2018	0	-12	N/A	-9	N/A
12/31/2017	0	-11	N/A	-8	N/A
9/30/2017	0	-10	N/A	-8	N/A
6/30/2017	N/A	-8	N/A	-8	N/A
3/31/2017	N/A	0	N/A	-8	N/A
12/31/2016	N/A	-2	N/A	-7	N/A
9/30/2016	N/A	-3	N/A	-6	N/A
6/30/2016	N/A	28	N/A	-5	N/A
3/31/2016	N/A	-38	N/A	-4	N/A
12/31/2015	N/A	-34	N/A	-4	N/A
9/30/2015	N/A	-33	N/A	-4	N/A
6/30/2015	N/A	-63	N/A	-3	N/A
3/31/2015	N/A	-2	N/A	-3	N/A
12/31/2014	N/A	-31	N/A	-2	N/A
9/30/2014	N/A	-34	N/A	-1	N/A
6/30/2014	N/A	-33	N/A	-1	N/A
3/31/2014	N/A	-35	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MRKR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: MRKR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: MRKR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: MRKR şirketinin gelirinin (yıllık 70.7% ) US pazarından (yıllık 9.2% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MRKR şirketinin gelirinin (yıllık 70.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MRKR 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/24 15:37
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Marker Therapeutics, Inc. 8 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kristen Kluska	Cantor Fitzgerald & Co.
Yun Zhong	Janney Montgomery Scott LLC
Aydin Huseynov	Ladenburg Thalmann & Company

Marker Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Consensus revenue estimates fall by 41%

Price target decreased to US$3.63

Price target decreased to US$5.63

Recent updates

Marker Therapeutics, Inc. announced that it has received $16.1 million in funding

Marker Therapeutics, Inc. announced that it expects to receive $16.1 million in funding

Marker Therapeutics, Inc. Provides Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Receives $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas to Support the Investigation of Mt-601 in Patients with Pancreatic Cancer

Marker Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $11.431731 million.

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.47 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.27 loss per share (vs US$0.48 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Marker Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$1.59 loss per share (vs US$3.58 loss in FY 2022)

Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

New major risk - Share price stability

Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study

Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse

Second quarter 2023 earnings released: US$0.47 loss per share (vs US$1.11 loss in 2Q 2022)

Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen (Multitaa)-Specific T Cell Product Candidate, Mt-401

Marker Therapeutics, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration

Marker Therapeutics, Inc. Reports Pre-Clinical Data of Its MT-601 multiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics, Inc. Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Marker Therapeutics Announces U.S. Food and Drug Administration Clearance of IND for MT-601, Its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Consensus revenue estimates increase by 277%

Price target decreased to US$2.17

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Resignation of Anthony Kim as Chief Financial Officer, Effective September 30, 2022

Marker Therapeutics Wins $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 Artemis Trial of Mt-401 in Post-Transplant AML

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Nasdaq Grants an Additional 180-Calendar Day Compliance Period to Marker Therapeutics to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 41%

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Marker Therapeutics, Inc. Announces FDA Clearance of IND for Mt-601, the Six-Antigen Targeted T Cell Therapy for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Price target decreased to US$3.63

Marker Therapeutics, Inc., Annual General Meeting, May 24, 2022

Marker Therapeutics, Inc. Announces Frederick Wasserman Will Not Stand for Reelection as Director

Full year 2021 earnings: EPS misses analyst expectations

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics, Inc. Announces Clinical Program Updates and Pipeline Expansion

Price target decreased to US$5.63

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from Russell 3000E Value Index

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Earnings beat expectations, revenue disappoints

Marker Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Trial of Mt-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

New 90-day high: US$3.19

Marker shares rise as it completes construction of its cGMP manufacturing facility

New 90-day high: US$1.79

Marker Therapeutics, Inc. Announces U.S. Food and Drug Administration Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.75

Earnings beat expectations

Marker Therapeutics EPS misses by $0.02

New 90-day low: US$1.43

New 90-day low: US$1.50

Marker Therapeutics, Inc.(NasdaqGM:MRKR) dropped from S&P Global BMI Index

New 90-day low - US$1.65

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin